Skip to content

Post-Market Clinical Follow-Up Study for Endoscopic Linear Cutter, Endoscopic Linear Cutter Reload and Endoscopic Linear Cutter Cartridge

Post-Market Clinical Follow-Up Study for Endoscopic Linear Cutter, Endoscopic Linear Cutter Reload and Endoscopic Linear Cutter Cartridge

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111593
Enrollment
Unknown
Registered
2025-11-03
Start date
2025-11-03
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Case group:None

Sponsors

Hebei Provincial Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, no gender restrictions; 2. Surgical approach: endoscopic surgery; 3. Surgical type: any of the following: general surgery or thoracic surgery; 4. Research instruments used intraoperatively: all marketed staplers and component models/specifications listed in Section 2.4.

Exclusion criteria

Exclusion criteria: 1. For use on inflamed, oedematous, ischaemic, necrotic tissue or tumour tissue; 2. Surgical or off-label use involving compression of tissue thicknesses below or exceeding the device's specified range; 3. For use on the liver or spleen; 4. Use on vascular tissue, the heart, the central circulatory system, or the central nervous system; 5. Use in combination with other similar products (stapler components) for resection, transection, or anastomosis at the surgical site; 6. Cases where surgical records are incomplete and key indicator information cannot be retrieved; 7. Pregnant women or women who are breastfeeding.

Design outcomes

Primary

MeasureTime frame
Anastomosis success rate;

Secondary

MeasureTime frame
Anastomotic leakage rate;Post-operative bleeding/hemorrhage rate;Wound infection rate;Anastomotic stenosis/stricture rate;Postoperative pancreatic fistula rate;Bronchopleural fistula rate;Abscess rate;Adverse events;Device deficiencies;Serious adverse events;

Countries

China

Contacts

Public ContactLizhong Shen

Hebei Provincial Traditional Chinese Medicine Hospital

shnlzh@163.com+86 188 3066 3708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026